Diabetic foot MRI: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 2: Line 2:
{{Diabetic foot}}
{{Diabetic foot}}
{{CMG}} {{AE}} {{Anahita}}
{{CMG}} {{AE}} {{Anahita}}


==Overview==
==Overview==


==MRI==
==MRI==
*[[Magnetic resonance imaging]] ([[Magnetic resonance imaging|MRI]] is specific for [[osteomyelitis]] [[diagnosis]].<ref name="pmid9431370">{{cite journal| author=Lipsky BA| title=Osteomyelitis of the foot in diabetic patients. | journal=Clin Infect Dis | year= 1997 | volume= 25 | issue= 6 | pages= 1318-26 | pmid=9431370 | doi=10.1086/516148 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=9431370  }} </ref>
*[[Magnetic resonance angiography]] ([[Magnetic resonance angiography|MRA]]) can be helpful in evaluation of [[Limb (anatomy)|limb]] [[perfusion]]. Nevertheless it has limited spatial resolution and reports could be influenced by previous [[stents]] or [[Implant (medicine)|implants]].<ref name="LepäntaloApelqvist2011">{{cite journal|last1=Lepäntalo|first1=M.|last2=Apelqvist|first2=J.|last3=Setacci|first3=C.|last4=Ricco|first4=J.-B.|last5=de Donato|first5=G.|last6=Becker|first6=F.|last7=Robert-Ebadi|first7=H.|last8=Cao|first8=P.|last9=Eckstein|first9=H.H.|last10=De Rango|first10=P.|last11=Diehm|first11=N.|last12=Schmidli|first12=J.|last13=Teraa|first13=M.|last14=Moll|first14=F.L.|last15=Dick|first15=F.|last16=Davies|first16=A.H.|title=Chapter V: Diabetic Foot|journal=European Journal of Vascular and Endovascular Surgery|volume=42|year=2011|pages=S60–S74|issn=10785884|doi=10.1016/S1078-5884(11)60012-9}}</ref>
*[[Magnetic resonance angiography]] ([[Magnetic resonance angiography|MRA]]) can be helpful in evaluation of [[Limb (anatomy)|limb]] [[perfusion]]. Nevertheless it has limited spatial resolution and reports could be influenced by previous [[stents]] or [[Implant (medicine)|implants]].<ref name="LepäntaloApelqvist2011">{{cite journal|last1=Lepäntalo|first1=M.|last2=Apelqvist|first2=J.|last3=Setacci|first3=C.|last4=Ricco|first4=J.-B.|last5=de Donato|first5=G.|last6=Becker|first6=F.|last7=Robert-Ebadi|first7=H.|last8=Cao|first8=P.|last9=Eckstein|first9=H.H.|last10=De Rango|first10=P.|last11=Diehm|first11=N.|last12=Schmidli|first12=J.|last13=Teraa|first13=M.|last14=Moll|first14=F.L.|last15=Dick|first15=F.|last16=Davies|first16=A.H.|title=Chapter V: Diabetic Foot|journal=European Journal of Vascular and Endovascular Surgery|volume=42|year=2011|pages=S60–S74|issn=10785884|doi=10.1016/S1078-5884(11)60012-9}}</ref>
*Usage of [[Contrast medium|contrast materials]] such as gadolinium is not recommended in [[diabetes|diabetic]] [[patients]] due to high risk of [[Renal insufficiency|renal failure]].<ref name="PrinceZhang2008">{{cite journal|last1=Prince|first1=Martin R.|last2=Zhang|first2=Honglei|last3=Morris|first3=Michael|last4=MacGregor|first4=Jennifer L.|last5=Grossman|first5=Marc E.|last6=Silberzweig|first6=Jeffrey|last7=DeLapaz|first7=Robert L.|last8=Lee|first8=Henry J.|last9=Magro|first9=Cynthia M.|last10=Valeri|first10=Anthony M.|title=Incidence of Nephrogenic Systemic Fibrosis at Two Large Medical Centers|journal=Radiology|volume=248|issue=3|year=2008|pages=807–816|issn=0033-8419|doi=10.1148/radiol.2483071863}}</ref><ref name="RydahlThomsen2008">{{cite journal|last1=Rydahl|first1=Casper|last2=Thomsen|first2=Henrik S.|last3=Marckmann|first3=Peter|title=High Prevalence of Nephrogenic Systemic Fibrosis in Chronic Renal Failure Patients Exposed to Gadodiamide, a Gadolinium-Containing Magnetic Resonance Contrast Agent|journal=Investigative Radiology|volume=43|issue=2|year=2008|pages=141–144|issn=0020-9996|doi=10.1097/RLI.0b013e31815a3407}}</ref>
*Usage of [[Contrast medium|contrast materials]] such as gadolinium is not recommended in [[diabetes|diabetic]] [[patients]] due to high risk of [[Renal insufficiency|renal failure]].<ref name="PrinceZhang2008">{{cite journal|last1=Prince|first1=Martin R.|last2=Zhang|first2=Honglei|last3=Morris|first3=Michael|last4=MacGregor|first4=Jennifer L.|last5=Grossman|first5=Marc E.|last6=Silberzweig|first6=Jeffrey|last7=DeLapaz|first7=Robert L.|last8=Lee|first8=Henry J.|last9=Magro|first9=Cynthia M.|last10=Valeri|first10=Anthony M.|title=Incidence of Nephrogenic Systemic Fibrosis at Two Large Medical Centers|journal=Radiology|volume=248|issue=3|year=2008|pages=807–816|issn=0033-8419|doi=10.1148/radiol.2483071863}}</ref><ref name="RydahlThomsen2008">{{cite journal|last1=Rydahl|first1=Casper|last2=Thomsen|first2=Henrik S.|last3=Marckmann|first3=Peter|title=High Prevalence of Nephrogenic Systemic Fibrosis in Chronic Renal Failure Patients Exposed to Gadodiamide, a Gadolinium-Containing Magnetic Resonance Contrast Agent|journal=Investigative Radiology|volume=43|issue=2|year=2008|pages=141–144|issn=0020-9996|doi=10.1097/RLI.0b013e31815a3407}}</ref>

Revision as of 16:31, 6 July 2021

Diabetic foot Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Diabetic foot from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Diabetic foot MRI On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Diabetic foot MRI

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Diabetic foot MRI

CDC on Diabetic foot MRI

Diabetic foot MRI in the news

Blogs on Diabetic foot MRI

Directions to Hospitals Treating Diabetic foot

Risk calculators and risk factors for Diabetic foot MRI

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Anahita Deylamsalehi, M.D.[2]

Overview

MRI



References

  1. Lipsky BA (1997). "Osteomyelitis of the foot in diabetic patients". Clin Infect Dis. 25 (6): 1318–26. doi:10.1086/516148. PMID 9431370.
  2. Lepäntalo, M.; Apelqvist, J.; Setacci, C.; Ricco, J.-B.; de Donato, G.; Becker, F.; Robert-Ebadi, H.; Cao, P.; Eckstein, H.H.; De Rango, P.; Diehm, N.; Schmidli, J.; Teraa, M.; Moll, F.L.; Dick, F.; Davies, A.H. (2011). "Chapter V: Diabetic Foot". European Journal of Vascular and Endovascular Surgery. 42: S60–S74. doi:10.1016/S1078-5884(11)60012-9. ISSN 1078-5884.
  3. Prince, Martin R.; Zhang, Honglei; Morris, Michael; MacGregor, Jennifer L.; Grossman, Marc E.; Silberzweig, Jeffrey; DeLapaz, Robert L.; Lee, Henry J.; Magro, Cynthia M.; Valeri, Anthony M. (2008). "Incidence of Nephrogenic Systemic Fibrosis at Two Large Medical Centers". Radiology. 248 (3): 807–816. doi:10.1148/radiol.2483071863. ISSN 0033-8419.
  4. Rydahl, Casper; Thomsen, Henrik S.; Marckmann, Peter (2008). "High Prevalence of Nephrogenic Systemic Fibrosis in Chronic Renal Failure Patients Exposed to Gadodiamide, a Gadolinium-Containing Magnetic Resonance Contrast Agent". Investigative Radiology. 43 (2): 141–144. doi:10.1097/RLI.0b013e31815a3407. ISSN 0020-9996.


Template:WikiDoc Sources